A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects

A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects With Malignancies

Purpose:

The purpose of this study is to compare the efficacy and safety of AD 923 to the most widely used current treatment (MSIR) in the management of target BTP in subjects with malignancies who are taking a stable dose of background opioids. The efficacy evaluation criteria have been designed to determine whether AD 923 provides superior analgesia compared with MSIR as measured by the primary endpoint.

Study Overview

• Status: Terminated
• Conditions: Pain; Cancer
• Intervention / Treatment: Drug: AD 923

• Study Type: Interventional
• Enrollment (Anticipated): 150
• Phase: Phase 3

Contacts and Locations

Study Locations

• United Kingdom
  • Essex
    • Saffron Walden, Essex, United Kingdom, CB10 1XL
      • Sosei R&D Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Inclusion Criteria:

• The subject is a male or female, at least 18 years of age.
• The subject has a malignancy, is receiving opioid therapy for his or her underlying persistent cancer pain, and is tolerant to the opioid therapy.
• The subject typically has 2 to 6 episodes of target BTP per day that require treatment.
• The subject has a life expectancy of >3 months.
• The subject or his or her caregiver has easy, reliable access to a telephone.

Main Exclusion Criteria:

• The subject is a female who is pregnant or lactating.
• The subject has any respiratory or cardiac condition that, in the opinion of the investigator, may be clinically worsened by opioids.
• The subject has any allergy to the AD 923 product or excipients, namely: fentanyl, dehydrated alcohol, menthol, saccharin, and citrate buffer; or to the MSIR product excipients, namely: morphine sulphate, lactose (anhydrous), pregelatinized maize starch, povidone, purified water, magnesium stearate, talc, and tablet coatings.
• The subject has any neurological or psychiatric disease that, in the opinion of the investigator, would compromise data collection.
• The subject has uncontrolled or rapidly escalating pain.
• The subject has any significant laboratory test results that, in the opinion of the investigator, will compromise subject safety or the conduct of the study.
• The subject has plans to undergo chemotherapy, radiotherapy, or surgery during the treatment period. The exception is that subjects may continue chemotherapy over the study period, provided it is not expected to alter the pain state or response to pain medication.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AD 923	Drug: AD 923
Active Comparator: MSIR	Drug: AD 923

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.

Secondary Outcome Measures

Outcome Measure
To assess the safety and tolerability of AD 923 in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.

Collaborators and Investigators

• Sponsor: Sosei
• Investigators: Principal Investigator: Andrew Davies, MBBS, Royal Marsden NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start: February 1, 2008

Study Registration Dates

• First Submitted: March 4, 2008
• First Submitted That Met QC Criteria: March 12, 2008
• First Posted (Estimate): March 13, 2008

Study Record Updates

• Last Update Posted (Estimate): June 6, 2008
• Last Update Submitted That Met QC Criteria: June 5, 2008
• Last Verified: June 1, 2008

More Information

Terms related to this study

• Keywords: Cancer Breakthrough Pain
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Breakthrough Pain
• Other Study ID Numbers: P-AD923-005